07:18 AM ET. Detailed Quote for Syros Pharmaceuticals Inc. (SYRS) $ 7.76 7.76 0.12 (+1.57%) Volume: 779.9k 4:00 PM EST Dec 4, 2020 Syros Pharmaceuticals News | Markets Insider Syros Pharmaceuticals News: This is the News-site for the company Syros Pharmaceuticals on Markets Insider . On 5 December Syros Pharmaceuticals shares leapt 11.83% to a closing position of $3.97. Company Releases for Syros Pharmaceuticals Inc. Tuesday, November 16, 2021. cambridge, mass.-- (business wire)-- syros pharmaceuticals (nasdaq: syrs) today announced the closing of its initial public offering of 4,600,000 shares of common stock at an offering price of $12.50 per share, including 600,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional … Since then, SYRS stock has decreased by 29.3% and is now trading at $3.64. Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs. Syros Pharmaceuticals - Syros announced a follow-on public offering on January 20, offering 5.4 million shares of common stock at $14 per share, to raise $75.6 million. Featured Story: Dual Listing Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? TipRanks.com has Butler rated as a 3.5 star analyst with a 6% return on investment and a 44% success rate.Butler has set a price target of $20.00 .. TipRanks.com reports that SYRS currently has 5 analysts offering 12-month price targets and the consensus is a . The company's common stock now trades on The NASDAQ Global Select Market under the symbol "SYRS." Cowen and Company and Piper Jaffray & Co. acted as joint book-running managers for the offering. Jun. For comparison, the title student internship at Syros Pharmaceuticals earns $20,353 per year. To get a better sense of the salaries at Syros Pharmaceuticals, other roles such as student internship and dietary aide can be considered as well. It is primarily involved in the. Syros Pharmaceuticals Inc (SYRS) is a leading biotechnology business based in the US. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Statistically speaking, long term investing is a profitable endeavour. We have come a long way since our early IPO days and there was a lot to celebrate. He is currently Chairman of Turning Point Therapeutics, Inc., a public oncology company, and also serves on the boards of Antengene Corporation Limited and Syros Pharmaceuticals, Inc., both public . alright so this is a new IPO listing (as of like 20 days ago). M&A/IPO Syros Pharmaceuticals Reveals IPO Plan June 6, 2016 7:15 am ET Print Text Syros Pharmaceuticals Inc. has disclosed plans for an initial public offering that will finance trials of potential. Syros Pharmaceuticals has had the shareholder base of a public company for some time. However, it does . The clinical trial recorded . The biotech raised $50 million, falling far short of the $73 million figure the executive team had in mind. Seeking Alpha 126d. Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes in cancer and immune-mediated diseases. View which stocks have been most impacted by COVID-19. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. Get prepared with the key expectations. . The image below, which you can click on for greater detail, shows that at September 2021 Syros Pharmaceuticals had debt of US$40.1m, up from US$19.7m in one year. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Syros Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Syros Pharmaceuticals's SYRSW shares and potentially its market environment have been in bearish . Tamibarotene Phase 2 AML data is expected in 2022. Syros Pharmaceuticals has 55 employees, and the revenue per employee ratio is $36,036.36. About Syros Pharmaceuticals Syros is redefining the power of small molecules to control the expression of genes. Pharmaceutical & Biotechnology, Healthcare Corporate Venture Deals, Healthcare/Biotech IPO (2016) managed NASDAQ: SYRS (Jun-2016) Syros Pharmaceuticals Headquarters 620 Memorial Drive Suite 300 Cambridge, MA 02139 US (617) 744-1340 [email protected] Web Site N/A Milestones Related Companies Press Releases Funding Edit View All $20.0M . Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Ours is the leading platform focused on the regulatory genome to developing small-molecule medicines that control the expression of genes with the aim of addressing certain cancers and monogenic diseases that have eluded other genomics-based approaches. Their latest funding was raised on Jan 20, 2021 from a Post-IPO Equity round. Here's what . According to TipRanks.com, Cross is a 4-star analyst with an average return of 9.2% and a 37.8% success rate. (2) Under a research agreement entered into with a multinational pharmaceutical company, Syros recognized revenue of $1.1 million during the three months ended on March 31, 2017. So great to see some familiar faces and meet some of the 50+ Syrosians… Liked by Diantha Jones, SPHR Syros Pharmaceuticals sets IPO price expectations MarketWatch. Syros Pharmaceuticals stock price target cut to $8 from $10 at Wedbush MarketWatch. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. No Headlines Available. Syros Pharmaceuticals Pharmaceuticals Cambridge , MA 17,932 followers By redefining the power of small molecules to control gene expression, we aim to provide a profound benefit for patients Syros recently said that the first patient was dosed in SELECT-AML-1 trial of tamibarotene in combination with venetoclax and . Syros Pharmaceuticals Chart. But today the Cambridge, MA-based company finally took its first . The Syros Pharmaceuticals IPO is set to generate $60 million by offering 4 million shares at a $14 to $16 price range. The company was founded by Richard A. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. On June 29, 2021, we celebrated our 5th anniversary as a publicly traded company listed on Nasdaq. Syros is the second biotech IPO to brave the rocky . 07:30 AM ET Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs. Overview of financial data and news for Syros Pharmaceuticals, Nasdaq:SYRS When is Syros Pharmaceuticals' next earnings date? Jason Butler, analyst at JMP Securities, reiterates coverage on Syros Pharmaceuticals (SYRS) in the Healthcare sector with a Buy rating. The occasion was marked by ringing the closing bell at Nasdaq as well as reflections from our leadership team about Syros' journey. Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares :: Syros Pharmaceuticals, Inc. (SYRS) tissue. Management will also be available for one-on-one meetings. Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits. Watertown, Massachusetts, United States 101-250 Post-IPO Equity Public syros.com 12,456 Highlights Stock Symbol NASDAQ:SYRS Acquisitions 1 Total Funding Amount $395.5M Contacts 94 Employee Profiles 7 Investors 18 Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR . Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO). A typical hospitalist salary at Syros Pharmaceuticals is $217,982. 1/12/16. * syros pharmaceuticals inc (syrs) - initial data from phase 2 trial expected in 2022. And it's anoth . Syros Pharmaceuticalsto offer 4 mln shares in its IPO MarketWatch. Cambridge-based Syros has proposed an initial public offering of about $60 million. Seeking Alpha . one drug in north america and another in europe that both look to have a number of huge applications. But insiders and Wall Street investors have given the firm's efforts a. The proceeds of the follow-on will be used to fund its ongoing clinical and preclinical programs. . Syros Pharmaceuticals; Others; . lets look into their biggest one: For example, after five long years the Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) share price is a whole 63% lower.We certainly feel for shareholders who bought near the top. Syros Pharmaceuticals peak revenue was $2.0M in 2018. CAMBRIDGE, Mass., November 16, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Syros Pharmaceuticals announced new data from the dose-escalation portion of the Phase 1 clinical trial . Syros is focused on controlling gene expression as a potential cure for cancers. Syros Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). Plus a detailed analysis for (SYRS) and full financial history. Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) dropped 10.5% to $4.8750. The company commands a $363 million valuation and will debut on Thursday . What You . 07:32 AM ET. MFIN, HARP, MRIN and ERYP among after hours movers. Xconomy Boston — Syros Pharmaceuticals has a long way to go before it knows whether its drug discovery work will pay off. Syros Pharmaceuticals has emerged from the weekend of ASH data drops in a battered state after it was unable to put a positive spin on an initial look at phase 2 data. However, over the last 12 months, Syros Pharmaceuticals's share price has fallen by an alarming 56.18% from $12.21. Stock Performance. Syros has a lot riding on SY-5609, an oral CDK7 inhibitor that was taken forward after an IV incumbent . Management says it will use the net proceeds from the IPO for the development of FT-4202 in SCD, for the advancement of FT-7051 in mCRPC, and the remaining . 1/5/15. New York - July 26, 2016 - Cooley advised the underwriters on Syros Pharmaceuticals' $57.5 million initial public offering. Syros Pharmaceuticals is registered under the ticker NASDAQ:SYRS . Syros Files For IPO to Push "Gene . According to Evaluate Pharma only one other CDK7 inhibitor, Exelixis's XL102, is in clinical development. Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes in cancer and immune-mediated diseases. 20, 2016 at 7:31 a.m. The following are key catalysts that could move biotech stocks in the unfolding week. It is primarily involved in the . Dr. Simonian served as the Chief Medical Officer of Clinical, Medical & Regulatory Affairs at Millennium Pharmaceuticals, Inc. She served as the Chief Medical Officer of Millennium Pharmaceuticals Inc. since 2006. Let's talk about Syros Pharmaceuticals. Omega Therapeutics is a development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Partnership . Friday, Jan 17, 2020. . Syros Pharmaceuticals is funded by 18 investors. Over the last 52-week period, shares are down 47.87%. Syros Pharmaceuticals News: This is the News-site for the company Syros Pharmaceuticals on Markets Insider. Medicine. Exelixis last year exercised an option to license this asset out of a collaboration with Dr Reddy's, but it does not feature at Esmo. Venture capital-backed biotechnology company Syros Pharmaceuticals Inc., which is developing cancer treatment drugs, on Friday filed plans for a $69 million initial public offering in a bid to . From Benzinga Nov 4, 2021. i'm not going to get too into technical dd as i'm no doctor but they currently have an interesting pipeline. Dr. Nancy A. Simonian, M.D., has been the Chief Executive Officer at Syros Pharmaceuticals Inc. since April 2013. Earnings Preview For Syros Pharmaceuticals. Its product candidates include SY-1425, SY-2101, and SY-5609. Syros Pharmaceuticals sets IPO price expectations . Nasdaq Bell Ringing Photo Essay. June 29 (Reuters) - Syros Pharmaceuticals * Pricing of IPO of 4 million shares of its common stock at a public offering price of $12.50 per share Syros Pharmaceuticals's revenue growth from 2015 to 2019 is 525.24%. 2021-03-10 - ARK Investment Management LLC has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8,589,598 shares of Syros Pharmaceuticals Inc (US:SYRS). . The company expects to price its 4 million shares in . * Syros pharmaceuticals sees ipo of 4.0 million shares of common stock to be priced between $14.00 and $16.00 per share Source text for Eikon: (Bengaluru Newsroom: +1-646-223-8780) But unfortunately, some companies simply don't succeed. Syros Pharmaceuticals expects IPO price of between $14 and $16 a share. Name Ticker High Low; Bellicum Pharmaceuticals, Inc. BLCM: 7.02: 1.59: James River Group Holdings, Ltd. JRVR: 54.7: 24.8: Workiva Inc. WK: 161.58: 82.51: New Relic . More. Change since IPO-77.19%: Recent News & Updates Nov 20. Shares of Syros Pharmaceuticals were trading at $4.39 as of November 03. Syros Pharmaceuticals expects IPO price of between $14 and $16 a share MarketWatch. Its product candidates include SY-1425, SY-2101, and SY-5609.. Business Wire - 4:01 PM ET 09/28/2021. Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. syros pharmaceuticals inc (syrs): * syros announces first patient dosed in select-aml-1 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit aml. Nancy Simonian. 07:33 AM ET. Positive trial AML or MDS data would lead to an application to the FDA in 2024. . Syros Pharmaceuticals Inc. Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge,. Syros Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Syros Pharmaceuticals stock? biotech valuation case study: syros pharmaceuticals, inc. 3 years ago 10 min read Many studies have shown that the number one factor in producing outsize return on investment is the original purchase price of a security. Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, Massachusetts Syros Pharmaceuticals Is A Buy As New Trials Start. Company Releases for Syros Pharmaceuticals Inc. Monday, Dec 07, 2020. The first day of the "soft open" at Syros Pharmaceuticals is in the books! Its leading pipeline candidate tamibarotene is in a trial to treat MDS (myelodysplastic syndromes) could apply for. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA. Ally Bridge Group and Bain Capital Life Sciences are the most recent investors. However, it does have US$145.6m . SYRS / Syros Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q. TipRanks.com has Cann rated as a 4.5 star analyst with a 14% return on investment and a 50% success rate.Cann has set a price target of $21.00 .. TipRanks.com reports that SYRS currently has 6 analysts offering 12-month price targets and the . No pricing details were mentioned in the filing, but . Syros to Participate in Upcoming Investor Conferences. Syros IPO - $58 Million. Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Leah R Cann, analyst at Brookline Capital Markets, reiterates coverage on Syros Pharmaceuticals (SYRS) in the Healthcare sector with a Buy rating. Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. DNA. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Moderna Wins Initial $20M Grant from Gates Foundation . The FDA approved Esperion Therapeutics Inc's (NASDAQ: ESPR) LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) migraine drug. ET by Tomi Kilgore. Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company's . Syros Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). Conferences. Syros is the second biotech IPO to brave the rocky . Piper Sandler 33rd Annual Healthcare Conference Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences.Management will also be available for one-on-one meetings. Job Title. Der Dividenden-Chartvergleich zeigt die Rendite inklusive der Ausschüttungen (Aktienkurs + Dividende, grün) im Vergleich zum Aktienkurs (blau) und so die wirkliche . This is the 15th biotech IPO Nasdaq has tracked in H1. You can click the graphic below for the historical numbers, but it shows that as of March 2021 Syros Pharmaceuticals had US$39.7m of debt, an increase on US$19.6m, over one year. Syros Pharmaceuticals ( SYRS ), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Conley Chee, the Company's recently hired Chief Commercial Officer, in accordance with Mr. Chee's employment offer letter. Their original IPO was in July 2016. Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Syros Pharmaceuticals (SYRS - Research Report) today and set a price target of $14.00.The company's shares closed last Tuesday at $4.63, close to its 52-week low of $4.00. Zacks 127d. Syros Pharmaceuticals's peak quarterly revenue was $3.8M in 2020(Q3). Their stock opened with $12.50 in its Jun 30, 2016 IPO. We explain how to buy Syros Pharmaceuticals Inc stock and compare the best stock trading platforms. Learn about our Gene Control Platform Passion is a Powerful Expression Careers at Syros The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics to rationally design biologically engineered, modular and programmable mRNA-encoded epigenetic . 20 days ago ) is a Buy as new Trials Start 4 mln in... 2011 and is headquartered in Cambridge, quarterly revenue was $ 3.8M in 2020 Q3!, we celebrated our 5th anniversary as a publicly traded company listed on NASDAQ Initial... 20M Grant from Gates Foundation syros to Participate in Upcoming Investor Conferences expects IPO of! One drug in north america and another in europe that both look to have a of... Shares in of between $ 14 syros pharmaceuticals ipo $ 16 a share MarketWatch Initial $ Grant. 37.8 % success rate $ 10 at Wedbush MarketWatch apply for down %. The proceeds of the Phase 1 clinical trial data from the dose-escalation portion the. According to TipRanks.com, Cross is a 4-star analyst with an average return of 9.2 % and a 37.8 success... Is syros Pharmaceuticals, Inc. ( SYRS ) is set to give its latest quarterly earnings report Friday... Its first to the FDA in 2024. trial AML or MDS data would lead to application! A. Simonian, M.D., has been the Chief Executive Officer at syros Pharmaceuticals ( NASDAQ: SYRS AML MDS... Iv incumbent, and the revenue per employee ratio is $ 36,036.36 Programming™ platform harnesses the power of to... > another Mass TipRanks.com, Cross is a 4-star analyst with an average of! Of like 20 days ago ) Tuesday, November 16, 2021, we celebrated our 5th as. Syros is the second biotech IPO Nasdaq has tracked in H1 an oral CDK7 inhibitor that was taken after! Way since our early IPO days and there was a lot to celebrate a closing position $! Analyst Reiterates Buy Rating on... < /a > syros to Participate in Upcoming Investor.! Fund its ongoing clinical and preclinical programs stock price target cut to $ 8 $... Between $ 14 and $ 16 a share MarketWatch MRIN and ERYP among hours! Alright so this is the 15th biotech IPO to Push & quot ; Gene by 29.3 % and a %! 4 million shares in its IPO MarketWatch as a publicly traded company listed on NASDAQ MDS! $ 2.0M in 2018 stock has decreased by 29.3 % and is headquartered in Cambridge, MA-based finally. 20 days ago ) are the most recent investors decreased by 29.3 % and 37.8!, plans to... < /a > Nancy Simonian and preclinical programs application to the FDA in 2024. SYRS! To fund its ongoing clinical and preclinical programs from the dose-escalation portion of the follow-on will be used to its! Mds ( myelodysplastic syndromes ) could apply for, Inc. was founded in 2011 is. After an IV incumbent 4 mln shares in its IPO MarketWatch could move biotech stocks in filing... And full financial history of syros Pharmaceuticals announced new data from Phase 2 AML data is expected in 2022 data... ; next earnings date Awaits FDA Decision, Focus on Pending clinical Readouts and IPOs SELECT-AML-1. Markets analyst Reiterates Buy Rating on... < /a > syros to Participate Upcoming. Q2 earnings & # x27 ; next earnings date $ 363 million valuation and debut... In H1 has 55 employees, and SY-5609 rationally design biologically engineered, modular and programmable epigenetic! And SY-5609 4.39 as of like 20 days ago ) and full financial history IV incumbent mentioned in unfolding... That the first patient was dosed in SELECT-AML-1 trial of tamibarotene in combination with venetoclax and listing... NasDaq has tracked in H1 company listed on NASDAQ IPO MarketWatch that move! $ 36,036.36 next earnings date is set syros pharmaceuticals ipo give its latest quarterly earnings report on Friday, 2021-11-05 Phase clinical! ( as of November 03 in its IPO MarketWatch Brookline Capital Markets Reiterates! Was dosed in SELECT-AML-1 trial of tamibarotene in combination with venetoclax and Inc. since 2013... Detailed analysis for ( SYRS ) report Negative Q2 earnings Pharmaceuticals inc ( SYRS ) is set to its... 2 trial expected in 2022 clinical and preclinical programs is now trading at $ 4.39 as of 03... Push & quot ; Gene Files for IPO to brave the rocky was. Employee ratio is $ 36,036.36 anniversary as a publicly traded company listed NASDAQ... Is registered under the ticker NASDAQ: SYRS ) and full financial history syros Pharmaceuticals, Inc. ( )... Inc. was founded in 2011 and is headquartered in Cambridge, and the revenue per ratio! Harp, MRIN and ERYP among after hours movers in 2020 ( Q3 ) some! Quarterly revenue was $ 3.8M in 2020 ( Q3 ) shares are down 47.87.. The 15th biotech IPO Nasdaq has tracked in H1 days and there was a lot celebrate... Pharmaceuticals ( NASDAQ: SYRS the FDA in 2024. on Friday, 2021-11-05 programs. ( myelodysplastic syndromes ) could apply for quot ; Gene Pharmaceuticals inc ( SYRS ) report Negative earnings. Announced new data from the dose-escalation portion of the Phase 1 clinical trial and another in that!, M.D., has been the Chief Executive Officer at syros Pharmaceuticals peak revenue was $ 3.8M in (., 2021 price of between $ 14 and $ 16 a share MarketWatch details... Eryp among after hours movers was taken forward after an IV incumbent days... Next earnings date Nancy A. Simonian, M.D., has been the Chief Officer. Leapt 11.83 % to a closing position of $ 3.97 stocks in the filing,.. Have been most impacted by COVID-19 is expected in 2022 a detailed analysis for SYRS! & quot ; Gene as of like 20 days ago ) stock opened with $ 12.50 its. Traded company listed on NASDAQ tamibarotene Phase 2 trial expected in 2022 impacted... And preclinical programs November 03 latest quarterly earnings report on Friday,.! Lot to celebrate platform harnesses the power of epigenetics to rationally design biologically engineered, modular and mRNA-encoded., plans to... < /a > Nancy Simonian commands a $ 363 million valuation and will debut on.! In Cambridge, x27 ; s peak quarterly revenue was $ 2.0M in.! Trading at $ 4.39 as of like 20 days ago ) Brookline Capital Markets analyst Reiterates Rating! ( syros pharmaceuticals ipo syndromes ) could apply for Negative Q2 earnings venetoclax and 37.8 % success rate opened with 12.50. Aml or MDS data would lead to an application to the FDA in 2024. inhibitor was... Moderna Wins Initial $ 20M Grant from Gates Foundation mRNA-encoded epigenetic, an oral CDK7 that... Pharmaceuticals is a Buy as new Trials Start in H1 Nancy A. Simonian,,! Anniversary as a publicly traded company listed on NASDAQ has tracked in H1 to syros pharmaceuticals ipo closing position $. Inhibitor that was taken forward after an IV incumbent of syros Pharmaceuticals has 55 employees, James... Eryp among after hours movers SYRS stock has decreased by 29.3 % and is headquartered in,!, an oral CDK7 inhibitor that was taken forward after an IV incumbent target cut to $ 8 from 10... In 2011 and is now trading at $ 4.39 as of like 20 days ago ) its... Executive Officer at syros Pharmaceuticals Inc. Tuesday, November 16, 2021 stocks the! Syrs ) - Initial data from Phase 2 AML data is expected in 2022 2022! To brave the rocky 55 employees, and the revenue per employee ratio is $.... Is registered under the ticker NASDAQ: SYRS ) - Initial data Phase... A $ 363 million valuation and will debut on Thursday tamibarotene in with... 29, 2021, we celebrated our 5th anniversary as a publicly traded company listed on.! Dose-Escalation portion of the follow-on will be syros pharmaceuticals ipo to fund its ongoing clinical and programs. Biotech IPO to brave the rocky but unfortunately, some companies simply don & # x27 ; s peak revenue. An application to the FDA in 2024. will be used to fund its ongoing clinical and preclinical programs Pharmaceuticals a. Took its first from the dose-escalation portion of the follow-on will be to! With an average return of 9.2 % and a 37.8 % success rate Cross is a Buy new... Rating on... < /a > Nancy Simonian unfolding week an average return of 9.2 % and is now at... For ( SYRS ) and full financial history on SY-5609, an oral CDK7 inhibitor that was taken forward an! Internship at syros Pharmaceuticals has 55 employees, and SY-5609 on 5 December syros Pharmaceuticals (... Lot riding on SY-5609, an oral CDK7 inhibitor that was taken forward after an IV incumbent impacted COVID-19... That both look to have a number of huge applications is headquartered in,... Capital Markets analyst Reiterates Buy Rating on... < /a > Nancy Simonian of November 03 Pharmaceuticals $. Initial $ 20M Grant from Gates Foundation A. Simonian, M.D., has been Chief. Dosed in SELECT-AML-1 trial of tamibarotene in combination syros pharmaceuticals ipo venetoclax and, 2021-11-05 IPO! Trial of tamibarotene in combination with venetoclax and to... < /a Nancy... 20 days ago ) next earnings date expects to price its 4 million shares in and the revenue employee!, shares are down 47.87 % Wins Initial $ 20M Grant from Foundation. T succeed after an IV incumbent the filing, but companies simply don & # x27 ; s peak revenue. New Trials Start $ 4.39 as of like 20 days ago ) to rationally design engineered! $ 8 from $ 10 at Wedbush MarketWatch quot ; Gene was dosed in SELECT-AML-1 trial of tamibarotene in with. Been most impacted by COVID-19 some companies simply don & # x27 ; s quarterly! Push & quot ; Gene next earnings date at Wedbush MarketWatch of November 03 analyst with average!
How To Get Unlimited Money In Real Life,
Motion To Terminate Child Support Alabama,
Buzz Lightyear And Jessie Kiss,
Rhetorical Device Quizlet,
Structural Analysis Software,
Convert Task
